| Nov 14 |
Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study
|
| Nov 13 |
Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits
|
| Nov 13 |
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
|
| Nov 13 |
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
|
| Nov 13 |
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
|
| Nov 13 |
Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision
|
| Nov 13 |
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
|
| Nov 13 |
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
|
| Nov 13 |
TRex Bio raises $84M to compete in crowded immune drug field
|
| Nov 12 |
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
|
